Salmeterol decreases eosinophilic cationic protein and rescue medication in patients inhaling beclomethasone dipropionate: Preliminary study in mild and moderate asthma in Trinidad, West Indies

International Journal of Clinical Pharmacology Research

Volumn 23, Issue 2-3, 2003, Pages 69-74

  Pinto Pereira, L M ^a   Clement, Y ^a   Rouse, J ^a   Matthew, J ^a   Asgarali, Z ^a   Ramoutar, D ^b   Teelucksingh, S ^a  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b Ministry of Health Trinidad and Tobago   (Trinidad and Tobago)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; SALBUTAMOL; SALMETEROL;

ADULT; AGED; AIRWAY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EOSINOPHIL; FEMALE; HUMAN; INFLAMMATION; MALE; PATHOGENESIS; PEAK EXPIRATORY FLOW; SPUTUM ANALYSIS; SYMPTOMATOLOGY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ALBUTEROL; ANTI-INFLAMMATORY AGENTS; ASTHMA; BECLOMETHASONE; BIOLOGICAL MARKERS; BLOOD PROTEINS; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; RIBONUCLEASES; TREATMENT OUTCOME; TRINIDAD AND TOBAGO;

EID: 1442289410     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Louis R., Lau L.C., Bron A.O., Roldaan A.C., Radermecker M., Djukanovic R. The relationship between airway inflammation and asthma severity. Am. J. Respir. Crit. Care Med., 161, 9, 2000.
2. Grootendorst D.C., van den Bos J.W., Romeijn J.J. et al. Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severity. Eur. Respir. J., 13, 647, 1999.
3. Ronchi M.C., Piragino C., Rosi E., et al. Do sputum eosinophils and ECP relate to the severity of asthma? Eur. Respir. J., 10, 1809, 1997.
4. Park J.W., Whang Y.W., Kim C.W., Park Y.B., Hong C.S. Eosinophil count and eosinophil cationic protein concentration of induced sputum in the diagnosis and assessment of airway inflammation in bronchial asthma. Allergy Asthma Proc., 19, 61, 1998.
5. Belda J., Giner J., Casan P., Sanchis J. Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up. Chest, 119, 1011, 2001.
6. Bacci E., Cianchetti S., Ruocco L., et al. Comparison between eosinophilic markers in induced sputum and blood in asthmatic patients. Clin. Exp. Allergy., 28, 1237, 1998.
7. Woolcock A., Lundback B., Ringdal N., Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med., 153, 1481, 1996.
8. Greening A.P., Ind P.W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids. Lancet, 344, 219, 1994.
9. Taylor D.R., Town G.I., Herbison G.P., et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax, 53, 744, 1998.
10. Cumming R.G., Mitchell P., Leeder S.R. Use of inhaled corticosteroids and the risk of cataracts. N. Engl. J. Med., 337, 8, 1997.
11. Toogood J.H.G., Baskerville J.C., Markov A.E., et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J. Allergy Clin. Immunol., 96, 157, 1995.
12. Sears M., Taylor D.R., Pring C.G., et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet, 336, 1391, 1990.
13. Spitzer W.O., Suissa S., Ernst P., et al. The use of β-agonists and the risk of death and near death from asthma. N. Engl. J. Med., 326, 501, 1992.
14. Cianchetti S., Bacci E., Ruocco L., et al. Salbutamol pre-treatment does not change eosinophil cationic concentration in hypertonic saline-induced sputum in asthmatic subjects. Clin. Exper. Allergy, 29, 712, 199.
15. Lai C.K., Chan C.H., Ho S.S., Hui A.C., Lai K.N. Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose corticosteroids. Chest, 108, 36, 1995.
16. Turner M.O., Johnston PR., Pizzichini E., Pizzichini M.M., Hussack RA., Hargreave F.E. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: A randomized, placebo controlled trial. Can. Respir. J., 5, 261, 1998.
17. Dente F. L., Bancalari L., Bacci E., et al. Effect of a single dose of salmeterol on the increase in airway eosinophil induced by allergen challenge in asthmatic patients. Thorax, 54, 622, 1999.
18. Bacci E., Di Franco A., Bartoli M.L., et al. Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma. Eur. Respir., 20, 66, 2000.
19. Personal communication, GlaxoSmithKline; data on file; see Web site at http://www.gsk.com.
20. Bhagat R., Kalra S., Swystun VA., Cockroft D.W. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest, 108, 1235, 1995.
21. Kalra S., Swystun VA., Bhagat R., Cockroft D.W. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest, 109, 953, 1996.
22. Ramage L., Lipworth B.J., Ingram C.G., Cree I.A., Dhillon D.P. Reduced protection against exercise-induced bronchoconstriction after chronic dosing with salmeterol. Respir. Med., 88, 363, 1994.
23. Drotar D.E., Davis E.E., Cockcroft D.W. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment. Ann. Allergy Asthma Immunol., 80, 31, 1998.
24. Nielsen L.P., Pedersen B., Faurschou P., Madsen F., Wilcke J.T., Dahl R. Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics. Respir. Med., 93, 863, 1999.